Verona Pharma's Presentation at ERS 2025 Highlights Ohtuvayre
At the upcoming European Respiratory Society (ERS) International Congress 2025, Verona Pharma plc (Nasdaq: VRNA) will share groundbreaking analyses from its Phase 3 ENHANCE studies focusing on Ohtuvayre (ensifentrine), a novel treatment aimed at chronic obstructive pulmonary disease (COPD). This event marks a significant step forward in the management of respiratory diseases and Ohtuvayre's pivotal role in today's therapeutic landscape.
What is Ohtuvayre?
Ohtuvayre stands out as a first-in-class treatment that uniquely combines the dual action of bronchodilation and non-steroidal anti-inflammatory properties in a single inhaled therapy. This is particularly noteworthy, as it represents the first new inhaled mechanism for COPD maintenance therapy in over two decades. As healthcare professionals and industry experts gather to discuss the latest advancements at the ERS, Verona Pharma's findings are anticipated to generate significant interest.
Innovative Analysis on Lung Function and Symptoms
The posters to be presented detail critical subgroup analyses concerning how ensifentrine affects lung function, as well as its influence on exacerbation rates and overall COPD symptoms, including shortness of breath and quality of life relative to baseline dyspnea levels. This comprehensive look into Ohtuvayre's efficacy will provide valuable insight into its potential as a go-to treatment in COPD management.
Key Sessions and Presenters
Among the significant highlights of the presentation is Poster 3613, focusing on the effect of ensifentrine on patients with varying levels of baseline dyspnea. This research will be presented by Dr. Jadwiga A. Wedzicha, a respected expert in the field from the National Heart and Lung Institute. Additionally, Poster 3614 will explore ensifentrine's impact on lung function and exacerbation rates, with insights from Dr. Frits M.E. Franssen of Maastricht University Medical Center.
About Verona Pharma
Verona Pharma is dedicated to developing and delivering innovative therapies that address the urgent needs of patients suffering from chronic respiratory diseases. Their commitment is illustrated through their rigorous dedication to clinical research and patient care. With Ohtuvayre as the cornerstone of their portfolio, Verona Pharma has made significant strides in shaping new therapeutic approaches that meet the complexities of respiratory diseases.
Future Development Plans
Verona is also advancing a fixed-dose combination of ensifentrine with glycopyrrolate, a long-acting muscarinic antagonist (LAMA), which aims to enhance treatment options for COPD patients further. Such advancements illustrate Verona Pharma's commitment not only to research but also to improving the lives of those affected by chronic respiratory issues.
Contact Information for Verona Pharma
For more information, individuals are encouraged to reach out to Verona Pharma via the following contacts:
Victoria Stewart
Senior Director of Investor Relations and Communications
Tel: +1-844-341-9901
Email: IR@veronapharma.com
Argot Partners
US Investor Enquiries
Tel: +1-212-600-1902
Email: verona@argotpartners.com
Ten Bridge Communications
International / US Media Enquiries
Tel: +1-781-316-4424
Email: tbcverona@tenbridgecommunications.com
Frequently Asked Questions
1. What is the significance of Ohtuvayre?
Ohtuvayre represents a significant advancement in COPD treatment, being the first inhaled therapy that merges bronchodilator and anti-inflammatory actions in one.
2. Who is presenting at the ERS Congress?
Dr. Jadwiga A. Wedzicha and Dr. Frits M.E. Franssen are the distinguished presenters of the key research on Ohtuvayre.
3. What outcomes are being analyzed in the Phase 3 studies?
The studies focus on lung function, exacerbation rates, and the quality of life in patients with COPD, providing essential insights into treatment effectiveness.
4. How does Verona Pharma support widespread access to its therapies?
Verona Pharma is committed to expanding access through innovative research and collaborations with healthcare providers and organizations.
5. Where can I find more information about Verona Pharma?
For additional information, visit the Verona Pharma website at www.veronapharma.com.
